Although sensitivity analyses restricted to semaglutide yielded consistent results, residual heterogeneity and confounding by indication cannot be excluded
L.BergoniaH.et al (2023)
More recently, in March 2024, Wegovy was This approval followed promising results from novo Nordisks SELECT trial, which followed 17,604 adults with obesity or overweight and cardiovascular disease but no history of diabetes
Wegovy est indicado para adultos con un ndice de masa corporal (IMC) inicial de superior a 30 (obesidad), o entre 27 y 30 (sobrepeso) en presencia de al menos una comorbilidad relacionada con el peso, por ejemplo, alteraciones de la glucemia (prediabetes o diabetes mellitus tipo 2), hipertensin, dislipidemia, apnea obstructiva del sueo o enfermedad cardiovascular
Akhtari, E., Raisi, F., Keshavarz, M., Hosseini, H., Sohrabvand, F., Bioos, S., Kamalinejad, M., & Ghobadi, A
These factors provide assurance in your weight loss journey at our semaglutide clinic in Surfside Beach